Viatris reports strong Q2 2023: revenue $3.92B, net income $264M, reaffirms guidance

Viatris Inc

2023-Q2 EPS reported $0.41 revenue$7,647,700,000

Total revenues $3.92B, U.S. GAAP net earnings $264M, adjusted EBITDA $1.31B, free cash flow $447M.
Reaffirms full-year 2023 total revenues, adjusted EBITDA and free cash flow expected at midpoint of guidance ranges.
Board declared $0.12/share dividend, payable Sept 15, record Aug 24 (unchanged from prior).
Paid down $727M debt YTD; on track to announce planned divestitures in 2023, with at least one significant in Q3.
Launched Breyna (generic Symbicort) in July; new product revenue target on track.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viatris Inc reported second quarter 2023 results: revenue $3.92 Billion, net income $264 Million. Guidance reaffirmed.

Period: second quarter 2023
Revenue: $3.92 Billion
Net income: $264 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] • Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Flow of $447 Million for the Quarter

View on SEC.gov

Browse all earnings releases →

Viatris Inc filing history →

Source: SEC EDGAR

accession 0001792044-23-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.